WO1997039326A3 - Dosage in vitro a polarisation de fluorescence - Google Patents

Dosage in vitro a polarisation de fluorescence Download PDF

Info

Publication number
WO1997039326A3
WO1997039326A3 PCT/US1997/006746 US9706746W WO9739326A3 WO 1997039326 A3 WO1997039326 A3 WO 1997039326A3 US 9706746 W US9706746 W US 9706746W WO 9739326 A3 WO9739326 A3 WO 9739326A3
Authority
WO
WIPO (PCT)
Prior art keywords
proteins
test substance
emission
mixture
pair
Prior art date
Application number
PCT/US1997/006746
Other languages
English (en)
Other versions
WO1997039326A2 (fr
Inventor
Berkley A Lynch
Ian A Macneil
Mark J Zoller
Original Assignee
Ariad Pharma Inc
Berkley A Lynch
Ian A Macneil
Mark J Zoller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ariad Pharma Inc, Berkley A Lynch, Ian A Macneil, Mark J Zoller filed Critical Ariad Pharma Inc
Priority to JP09530451A priority Critical patent/JP2000512737A/ja
Priority to AU28076/97A priority patent/AU727108B2/en
Priority to EP97922393A priority patent/EP0898709A2/fr
Publication of WO1997039326A2 publication Critical patent/WO1997039326A2/fr
Publication of WO1997039326A3 publication Critical patent/WO1997039326A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching

Abstract

L'invention concerne un procédé de dosage in vitro permettant d'identifier une substance test qui inhibe l'association mutuelle d'une paire de protéines. Ce procédé consiste à produire une paire de protéines aptes à s'associer, l'une des protéins étant porteuse d'une substande fluorescente liée de manière covalente; à préparer un mélange contenant les deux protéins et au moins une substance test; à irradier le mélange avec de la lumière polarisée d'une longueur d'onde appropriée permettant l'excitation de la substance fluorescente telle que l'indique l'émission de lumière polarisée; à mesurer le degré de polarisation de l'émission et à déterminer l'effet dû à la présence ou à la concentration de la substance test en réduisant la polarisation de l'émission observée d'un mélange de deux protéines seules. L'activité inhibitrice de la substance test est en corrélation avec les valeurs réduites de dépolarisation.
PCT/US1997/006746 1996-04-18 1997-04-18 Dosage in vitro a polarisation de fluorescence WO1997039326A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP09530451A JP2000512737A (ja) 1996-04-18 1997-04-18 試験管内蛍光偏光検定法
AU28076/97A AU727108B2 (en) 1996-04-18 1997-04-18 In vitro fluorescence polarization assay
EP97922393A EP0898709A2 (fr) 1996-04-18 1997-04-18 DOSAGE $i(IN VITRO) A POLARISATION DE FLUORESCENCE

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1559096P 1996-04-18 1996-04-18
US60/015,590 1996-04-18
US2987096P 1996-11-06 1996-11-06
US60/029,870 1996-11-06

Publications (2)

Publication Number Publication Date
WO1997039326A2 WO1997039326A2 (fr) 1997-10-23
WO1997039326A3 true WO1997039326A3 (fr) 1997-12-24

Family

ID=26687596

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/006746 WO1997039326A2 (fr) 1996-04-18 1997-04-18 Dosage in vitro a polarisation de fluorescence

Country Status (5)

Country Link
EP (1) EP0898709A2 (fr)
JP (1) JP2000512737A (fr)
AU (1) AU727108B2 (fr)
CA (1) CA2250067A1 (fr)
WO (1) WO1997039326A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0938586A4 (fr) * 1996-10-28 2002-01-30 Panvera Corp Mesure de l'activite de la kinase par polarisation de fluorescence
US7105307B2 (en) 1997-08-30 2006-09-12 Cyclacel, Ltd. Compositions and methods for screening for modulators of enzymatic activity
ATE317122T1 (de) 1997-09-05 2006-02-15 Matsushita Electric Ind Co Ltd Fluoreszierende polarisation
GB9923208D0 (en) * 1999-10-01 1999-12-08 Cambridge Drug Discovery Ltd Assay
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
US7198958B2 (en) 2001-07-02 2007-04-03 Arctic Diagnostics Oy Method for increasing hydrophilicity of fluorescent label compounds
ATE447178T1 (de) * 2001-07-02 2009-11-15 Arctic Diagnostics Oy Zwei photonen absorbierende bordipyrromethen- difluorid-farbstoffe und ihre anwendungen
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
CA2531506A1 (fr) 2003-08-22 2005-03-10 Avanir Pharmaceuticals Derives de naphtyridine substitues servant d'inhibiteurs de facteur d'inhibition de la migration des macrophages et leur utilisation pour traiter des maladies humaines
JP4607950B2 (ja) * 2004-03-18 2011-01-05 トランス テック ファーマ，インコーポレイテッド 蛍光偏光アッセイ
US7608407B2 (en) * 2004-11-16 2009-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Fluorescence polarization assay for determining histidine decarboxylase activity
CA2600175A1 (fr) 2005-03-24 2006-03-20 Avanir Pharmaceuticals Derives de thienopyridinone utilises en tant qu'inhibiteurs du facteur d'inhibition de la migration des macrophages
WO2013056720A1 (fr) 2011-10-18 2013-04-25 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Colorants fluorescents comportant des groupes hydroxyméthyle phosphorylés et leur utilisation en microscopie photonique et dans des techniques d'imagerie
EP2944958A1 (fr) 2014-04-04 2015-11-18 Techno-Path (Distribution) Procédé de prédiction d'instabilité phénotypique dans une cellule
US20170160286A1 (en) * 2014-07-15 2017-06-08 Valitacell Limited A Method of Measuring Antibody Concentration in a Sample
EP3075844A1 (fr) 2015-04-01 2016-10-05 Valitacell Limited Procédé de détermination d'une caractéristique fonctionnelle ou de composition d'un milieu de culture cellulaire

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4257774A (en) * 1979-07-16 1981-03-24 Meloy Laboratories, Inc. Intercalation inhibition assay for compounds that interact with DNA or RNA
EP0449269A1 (fr) * 1990-03-27 1991-10-02 Roche Diagnostics GmbH Méthode pour la détection des protéines contenant tyrosine phosphorylée
WO1993003377A1 (fr) * 1991-07-31 1993-02-18 Ziltener Hermann J Procede de detection de restes de phosphotyrosine
US5352660A (en) * 1991-10-31 1994-10-04 Mount Sinai Hospital Corporation Method for assaying for a substance that affects a SH2-phosphorylated ligand regulatory system
WO1997010253A1 (fr) * 1995-09-15 1997-03-20 Merck & Co., Inc. Dosage a rendement eleve utilisant des proteines hybrides

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4257774A (en) * 1979-07-16 1981-03-24 Meloy Laboratories, Inc. Intercalation inhibition assay for compounds that interact with DNA or RNA
EP0449269A1 (fr) * 1990-03-27 1991-10-02 Roche Diagnostics GmbH Méthode pour la détection des protéines contenant tyrosine phosphorylée
WO1993003377A1 (fr) * 1991-07-31 1993-02-18 Ziltener Hermann J Procede de detection de restes de phosphotyrosine
US5352660A (en) * 1991-10-31 1994-10-04 Mount Sinai Hospital Corporation Method for assaying for a substance that affects a SH2-phosphorylated ligand regulatory system
WO1997010253A1 (fr) * 1995-09-15 1997-03-20 Merck & Co., Inc. Dosage a rendement eleve utilisant des proteines hybrides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
B. A. LYNCH ET AL: "A fluorescence polarisation based Src-SH2 binding assay.", ANALYTICAL BIOCHEMISTRY., vol. 247, no. 1, 1997, NEW YORK US, pages 77 - 82, XP002045666 *
P. WU ET AL: "A high-throughput STAT binding assay using fluorescence polatization.", ANALYTICAL BIOCHEMISTRY., vol. 249, no. 1, 1997, NEW YORK US, pages 29 - 36, XP002045667 *

Also Published As

Publication number Publication date
CA2250067A1 (fr) 1997-10-23
EP0898709A2 (fr) 1999-03-03
JP2000512737A (ja) 2000-09-26
AU727108B2 (en) 2000-11-30
WO1997039326A2 (fr) 1997-10-23
AU2807697A (en) 1997-11-07

Similar Documents

Publication Publication Date Title
WO1997039326A3 (fr) Dosage in vitro a polarisation de fluorescence
Lai et al. Molecular mechanisms of synaptic vesicle priming by Munc13 and Munc18
AU5884394A (en) Method and device for assessing the suitability of biopolymers
DE69833378D1 (de) Fluoreszierende polarisation
ATE386815T1 (de) Methoden und syteme zur überwachung intrazellulärer bindereaktionen
ATE412050T1 (de) Fluoreszenzprotein-sensoren zur erkennung von analyten
WO2006023725A3 (fr) Systeme de detecteur de ph fluorescent et procedes associes
DE69130171T2 (de) Bestimmung von analyten durch übertragung von fluoreszenzenergie
DE69033067D1 (de) 4,7-dichlorfluoreszein-farbstoffe als molekulare sonden
CA2263888A1 (fr) Procedes et compositions servant a detecter le cancer du col de l'uterus
WO2001040757A3 (fr) Cavites optiques resonnantes destinees a des biodetecteurs a grande sensibilite et a haut rendement et procedes utilisant ces biodetecteurs
WO2004000884A3 (fr) Compositions et methodes pour le dosage de l'apo b48 et de l'apo b100
CA2217700A1 (fr) Procede de detection de substances biologiquement actives
AU1721092A (en) Merocyanine and nitro or nitroso substituted polyhalogenated phenolsulfonephthaleins as protein indicators in biological samples
DE69941688D1 (de) Immunoassays unter verwendung von sers (surface enhanced raman scattering)
Shang et al. In vitro study on the binding of neutral red to bovine serum albumin by molecular spectroscopy
WO2005019470A3 (fr) Detection et profilage de complexes moleculaires
PT696642E (pt) Processo para a identificacao de pertuebacoes do sistema proteina c / proteina s
DE60228196D1 (de) System und verfahren zur in-vitro-analyse von therapeutischen wirkstoffen
CA2339821A1 (fr) Mesure enzymatique de l'acide mycophenolique
WO2000023615A3 (fr) Procede ameliore destine a une extraction quantitative d'information se rapportant a une influence sur une reponse cellulaire
WO1999023466A3 (fr) Appareil et procedes permettant de mesurer la polarisation de fluorescence
Miyoshi et al. Investigation of the interaction mode of phenothiazine neuroleptics with α1‐acid glycoprotein
WO2002066982A3 (fr) Analyse de modifications et de demodifications de proteines avec des proteines apparentees a l'ubiquitine par fret (transfert d'energie de resonance par fluorescence)
CA2384170A1 (fr) Sonde de visualisation de gmp cyclique et procede de detection et de quantification de gmp cyclique faisant intervenir cette sonde

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2250067

Country of ref document: CA

Ref country code: CA

Ref document number: 2250067

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997922393

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997922393

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997922393

Country of ref document: EP